Zevra Therapeutics, Inc.
ZVRA
$8.08
-$0.13-1.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 481.73% | 495.65% | -6.79% | 27.63% | -47.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 481.73% | 495.65% | -6.79% | 27.63% | -47.47% |
| Cost of Revenue | 246.46% | 668.57% | 11.33% | 1,499.31% | 427.77% |
| Gross Profit | 1,441.32% | 486.34% | -8.69% | -49.40% | -88.76% |
| SG&A Expenses | 64.88% | 96.81% | 4.82% | 178.58% | 90.62% |
| Depreciation & Amortization | 4.53% | 5.69% | 109.33% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.29% | 7.75% | -2.20% | 69.78% | 91.85% |
| Operating Income | 48.19% | 73.83% | -1.71% | -77.73% | -280.60% |
| Income Before Tax | 487.34% | 88.52% | -2.39% | -226.05% | -650.09% |
| Income Tax Expenses | 3,041.43% | 1,788.57% | -- | -- | 194.59% |
| Earnings from Continuing Operations | 474.94% | 81.36% | -79.67% | -220.49% | -674.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 474.94% | 81.36% | -79.67% | -220.49% | -674.39% |
| EBIT | 48.19% | 73.83% | -1.71% | -77.73% | -280.60% |
| EBITDA | 51.97% | 80.38% | 4.19% | -67.88% | -260.11% |
| EPS Basic | 360.69% | 85.60% | -30.09% | -132.83% | -526.48% |
| Normalized Basic EPS | 51.05% | 91.14% | 26.75% | -134.64% | -478.52% |
| EPS Diluted | 352.08% | 85.60% | -30.09% | -132.83% | -532.41% |
| Normalized Diluted EPS | 52.40% | 91.14% | 26.75% | -134.64% | -478.52% |
| Average Basic Shares Outstanding | 30.74% | 29.48% | 38.11% | 37.68% | 23.60% |
| Average Diluted Shares Outstanding | 34.43% | 29.48% | 38.11% | 37.68% | 23.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |